Skip to main content
SpringerLink
Log in

Erbitux [cetuximab] is to be funded by the Ontario Government as a therapy for metastatic colorectal cancer

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Bristol-Myers Squibb Canada.ERBITUX(TM) now available in Ontario and BC for patients with advanced colorectal cancer - Addition of proven treatment increases options for patients. Media Release: 30 Sep 2009. Available from: URL: http://www.bms.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Erbitux [cetuximab] is to be funded by the Ontario Government as a therapy for metastatic colorectal cancer. Pharmacoecon. Outcomes News 591, 14 (2009). https://doi.org/10.2165/00151234-200905910-00038

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905910-00038

Keywords

Search

Navigation